Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Neo-CheckRay: safety findings of radiotherapy and immunotherapy in breast cancer

Alex De Caluwe • 14 Sep 2024
ESMO 2024
Breast Cancer Antibodies Checkpoint Inhibitors Durvalumab Oleclumab
Neo-CheckRay

Alex De Caluwe, MD, Jules Bordet Institute, Brussels, Belgium, discusses safety findings from the Neo-CheckRay trial (NCT03875573), which combines radiotherapy and immunotherapy in luminal B breast cancer. The novel concurrent approach, typically delivered post-surgery, was safe, with no concerning safety signals. Radiotherapy was not shown to be toxic, with no grade 3 or 4 adverse events and only minimal grade 1 and 2 side effects. These outcomes support the trial’s progression, suggesting a well-tolerated treatment profile. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex De Caluwe

Evaluating the emerging role of radiotherapy and immunotherapy in breast cancer
0:36
Evaluating the emerging role of radiotherapy and immunotherapy in breast cancer
Alex De Caluwe • 14 Oct 2024
Enhancing immunotherapy response in luminal B breast cancer with radiotherapy
1:08
Enhancing immunotherapy response in luminal B breast cancer with radiotherapy
Alex De Caluwe • 14 Sep 2024
Neo-CheckRay: boosting pCR rates in cold tumors
1:19
Neo-CheckRay: boosting pCR rates in cold tumors
Alex De Caluwe • 14 Sep 2024
Neo-CheckRay: chemotherapy and SBRT with durvalumab and oleclumab in ER+/HER2- breast cancer
0:54
Neo-CheckRay: chemotherapy and SBRT with durvalumab and oleclumab in ER+/HER2- breast cancer
Alex De Caluwe • 14 Sep 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals